Literature DB >> 32780227

Etoricoxib treatment prevented body weight gain and ameliorated oxidative stress in the liver of high-fat diet-fed rats.

Fariha Kabir1, Kamrun Nahar1, Md Mizanur Rahman1, Fariha Mamun1, Shoumen Lasker1, Ferdous Khan1, Tahmina Yasmin1, Khondker Ayesha Akter1, Nusrat Subhan1, Md Ashraful Alam2.   

Abstract

The main focus of this study was to determine the role of etoricoxib in counterbalancing the oxidative stress, metabolic disturbances, and inflammation in high-fat (HF) diet-induced obese rats. To conduct this study, 28 male Wistar rats (weighing 190-210 g) were distributed randomly into four groups: control, control + etoricoxib, HF, and HF + etoricoxib. After 8 weeks of treatment with etoricoxib (200 mg/kg), all the animals were sacrificed followed by the collection of blood and tissue samples in order to perform biochemical tests along with histological staining on hepatic tissues. According to this study, etoricoxib treatment prevented the body weight gain in HF diet-fed rats. Furthermore, rats of HF + etoricoxib group exhibited better blood glucose tolerance than the rats of HF diet-fed group. In addition, etoricoxib also markedly normalized HF diet-mediated rise of hepatic enzyme activity. Etoricoxib treatment lowered the level of oxidative stress indicators significantly with a parallel augmentation of antioxidant enzyme activities. Furthermore, etoricoxib administration helped in preventing inflammatory cell invasion, collagen accumulation, and fibrotic catastrophe in HF diet-fed rats. The findings of the present work are suggestive of the helpful role of etoricoxib in deterring the metabolic syndrome as well as other deleterious pathological changes afflicting the HF diet-fed rats.

Entities:  

Keywords:  COX-2; Etoricoxib; Inflammation; Metabolic syndrome; Obesity; Oxidative stress

Year:  2020        PMID: 32780227     DOI: 10.1007/s00210-020-01960-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Celecoxib, a selective cyclooxygenase-2 inhibitor, lowers plasma cholesterol and attenuates hepatic lipid peroxidation during carbon-tetrachloride-associated hepatotoxicity in rats.

Authors:  Martins Ekor; Adesina O Odewabi; Oluwafemi E Kale; Omolola A Adesanoye; Titilayo O Bamidele
Journal:  Drug Chem Toxicol       Date:  2011-12-15       Impact factor: 3.356

2.  Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.

Authors:  Magnus Bäck; Li Yin; Erik Ingelsson
Journal:  Eur Heart J       Date:  2011-11-21       Impact factor: 29.983

Review 3.  Contribution of Adipose Tissue Inflammation to the Development of Type 2 Diabetes Mellitus.

Authors:  Maggie S Burhans; Derek K Hagman; Jessica N Kuzma; Kelsey A Schmidt; Mario Kratz
Journal:  Compr Physiol       Date:  2018-12-13       Impact factor: 9.090

4.  Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice.

Authors:  Youngshim Choi; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  J Nutr Biochem       Date:  2016-09-22       Impact factor: 6.048

5.  Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.

Authors:  Enrique Chávez; José Segovia; Mineko Shibayama; Victor Tsutsumi; Paula Vergara; Luis Castro-Sánchez; Eduardo Pérez Salazar; Mario G Moreno; Pablo Muriel
Journal:  Liver Int       Date:  2010-05-26       Impact factor: 5.828

6.  Effects of acetyl salycilic acid and ibuprofen in chronic liver damage induced by CCl4.

Authors:  Enrique Chávez; Luis Castro-Sánchez; Mineko Shibayama; Victor Tsutsumi; Eduardo Pérez Salazar; Mario G Moreno; Pablo Muriel
Journal:  J Appl Toxicol       Date:  2011-02-24       Impact factor: 3.446

Review 7.  Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus.

Authors:  Zsolt Bagi; Nóra Erdei; Zoltán Papp; István Edes; Akos Koller
Journal:  Pharmacol Rep       Date:  2006       Impact factor: 3.024

Review 8.  Extracellular matrix and liver disease.

Authors:  Elena Arriazu; Marina Ruiz de Galarreta; Francisco Javier Cubero; Marta Varela-Rey; María Pilar Pérez de Obanos; Tung Ming Leung; Aritz Lopategi; Aitor Benedicto; Ioana Abraham-Enachescu; Natalia Nieto
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

Review 9.  Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.

Authors:  Naim Alkhouri; Laura J Dixon; Ariel E Feldstein
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-08       Impact factor: 3.869

10.  Adipose tissue transcriptome by serial analysis of gene expression.

Authors:  Carl Bolduc; Marianne Larose; Nicolas Lafond; Mayumi Yoshioka; Marc-André Rodrigue; Jean Morissette; Claude Labrie; Vincent Raymond; Jonny St-Amand
Journal:  Obes Res       Date:  2004-05
View more
  1 in total

Review 1.  Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.

Authors:  Afaf A El-Malah; Magdy M Gineinah; Pran Kishore Deb; Ahdab N Khayyat; Monika Bansal; Katharigatta N Venugopala; Anfal S Aljahdali
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.